FDA Basics Webinar: A Brief Overview of Risk Evaluation and Mitigation Strategies (REMS)
In 2007, a new law that gave FDA many new authorities and responsibilities to enhance drug safety was enacted. It’s called the Food and Drug Administration Amendments Act- sometimes called “FDAAA”- and one of its provisions gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.
A REMs may be required by the FDA as part of the approval of a new product, or for an approved product when new safety information arises. Essentially, a REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use.
Since medicines are very different from each other, each REMS for each medicine is also different.
This presentation will be held on November 20, 2012 at 1:00 PM EST and will discuss REMS and how they are used to help ensure that the benefits of certain medicines continue to outweigh their risks. To join the meeting, click here: https://collaboration.fda.gov/rems1/
For more information, visit the FDA Basics website.
Has this event been cancelled?
its awesome post. I would like to thanks for your this post creative writing abilities has inspired to me.I have been talking with my friend about your this post. So please keep it this type post. thanks
nice post. thanks to share this post..
Nice information, and thanks a lot.
Is this going to be added to youtube?
I’m now not positive the place you’re getting your info, but good topic. I must spend a while finding out much more or figuring out more. Thank you for fantastic info I used to be searching for this information for my mission.
Are these presentations uploaded to be viewed?
How are the REMS actually enforced if there is a new one for every “safety risk” product out there?
thanks for share,,,,
nice topic
Really great presentation, there is so much ignorance about this topic, and it’s really important for everyone of us, very nice work!!
Thanks for the info. It’s really dificult to track down reliable and informed comment regarding safely and in particular the current stategy.
It is like the French programme? I think they have something similar.
Thank you for that info and webinar, very valuable.
great article with great information.
REMS should include a medication guide, a patient package insert, a communication plan, elements to assure safe use, and an implementation system. Does all REMS programs will contain a timetable for assessment?
Really interesting post, I agree with several previous posters. I think the ipad is more for reading than writing.
I appreciate the sense that comes out from this post. Thank you!
I like the valuable information you provide in your articles.
I will bookmark your blog and check again here regularly.
I am quite sure I’ll learn a lot of new stuff right here! Good luck for the next!
Please let us know if youll post the recorded webinar on the site. We’d love to know
No new transparency posts since October?
What is the status of the Phase II transparency proposals (Public Disclosure)?
Hi there! This blog post couldn’t be written any better! Looking through this post reminds me of my previous roommate! He always kept preaching about this. I’ll send this article to him.
Fairly certain he’ll have a very good read. Thank you for sharing!